These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 17956259)
61. Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites. Zürcher M; Diederich F J Org Chem; 2008 Jun; 73(12):4345-61. PubMed ID: 18510366 [TBL] [Abstract][Full Text] [Related]
70. Bioconverted products of essential fatty acids as potential antimicrobial agents. Bajpai VK; Kim HR; Hou CT; Kang SC N Biotechnol; 2009 Oct; 26(3-4):122-30. PubMed ID: 19643210 [TBL] [Abstract][Full Text] [Related]
71. Druggability of the enzymes of the non-mevalonate-pathway. Masini T; Kroezen BS; Hirsch AK Drug Discov Today; 2013 Dec; 18(23-24):1256-62. PubMed ID: 23856326 [TBL] [Abstract][Full Text] [Related]
72. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
73. Coenzyme A biosynthesis: an antimicrobial drug target. Spry C; Kirk K; Saliba KJ FEMS Microbiol Rev; 2008 Jan; 32(1):56-106. PubMed ID: 18173393 [TBL] [Abstract][Full Text] [Related]
74. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
75. Riboflavin biosynthetic and regulatory factors as potential novel anti-infective drug targets. Long Q; Ji L; Wang H; Xie J Chem Biol Drug Des; 2010 Apr; 75(4):339-47. PubMed ID: 20148904 [TBL] [Abstract][Full Text] [Related]
76. Isocyanide-based multicomponent reactions in drug discovery. Akritopoulou-Zanze I Curr Opin Chem Biol; 2008 Jun; 12(3):324-31. PubMed ID: 18312861 [TBL] [Abstract][Full Text] [Related]